Table 1.
Characteristics of patients with key outcomes of the randomized controlled trials analysed in this meta-analysis
| Parameter | Lau et al.[7] | Enebo et al.[8] | Frias et al.[9] | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||
| Cagrilintide- 2.4 mg (n=102) | Liraglutide- 3.0 mg (n=99) | Placebo (n=101) | Cagrisema- 2.4 mg/ 2.4 mg (n=12) | Semaglutide- 2.4 mg with placebo (n=24) | Cagrilintde- 2.4 mg (n=30) | Cagrisema- 2.4 mg/ 2.4 mg (n=31) | Semaglutide- 2.4 mg (n=31) | |
| Age (years) | 52·7 (9·8) | 51·5 (9·3) | 51·4 (11·9) | 43.0 (8.1) | 41.0 (8.8) | 62 (7) | 56 (10) | 57 (10) |
| Male | 45 (45%) | 27 (26%) | 42 (42%) | 5 (42%) | 16 (67%) | 23 (77%) | 18 (58%) | 18 (58%) |
| Weight (kg) | 106·8 (24·1) | 107·8 (24·1) | 106·2 (21·6) | 92.1 (11.9) | 99.6 (15.6) | 107·4 (25·0) | 104·3 (23·2) | 105·4 (24·9) |
| BMI (kg/m2) | 37·9 (7·6) | 38·4 (7·4) | 37·4 (5·7) | 32.2 (2.5) | 32.2 (3.0) | 34·4 (6·1) | 35·9 (5·7) | 36·2 (7·2) |
| HBA1c (%) | 5·6% (0·4) | 5·6% (0·4) | 5·6% (0·4) | 5.2 (0.4) | 5.4 (0.4) | 8·1 (0·8) | 8·5 (0·8) | 8·6 (0·7) |
| Duration of T2D (years) | N/A | N/A | N/A | N/A | N/A | 10·7 (9·1) | 6·4 (3·8) | 9·2 (8·3) |
| eGFR (mL/min/1·73 m2) | N/a | N/a | N/a | N/a | N/a | 92 (13) | 94 (12) | 90 (18) |
| Metformin | N/A | N/A | N/A | N/A | N/A | 21 (70%) | 23 (74%) | 23 (74%) |
| Metformin+SGLT2i | N/A | N/A | N/A | N/A | N/A | 9 (30%) | 8 (26%) | 8 (26%) |
| Percent reduction in Weight (%) | −9.7 (0.6) | −9.0 (0.6) | −3.0 (0.6) | −17.1 (1.5) | −9.5 (1.0) | −15.6 (1.26) | −8.1 (1.23) | −5.1 (1.26) |
| Absolute Weight reduction (kg) | −9.5 (0.6) | −8.4 (0.6) | −2.8 (0.6) | −15.9 (1.4) | −8.7 (1.0) | −16.3 | 8.4 | −5.3 |
| HbA1c Reduction | −0.1 (0.3) | −0.3 (0.2) | −0.1 (0.2) | −0.3 (0.2) | −0.2 (0.2) | −0.9 (0.15) | −2.2 (0.15) | −-1.8 (0.16) |
| TIR by CGM (%) | N/a | N/a | N/a | N/A | N/A | 88.9% | 71.7% | 76.2% |
| SBP reduction (mm Hg) | −8.0 (1.3) | −4.3 (1.3) | −3.6 (1.3) | N/a | N/a | −3 | −13 | 1 |
| GI side effects | 52 (51%) | 59 (60%) | 32 (32%) | 11 (92%) | 19 (79%) | 10 (33%) | 18 (58%) | 10 (32%) |
| Anti-cagrilintide antibodies at baseline | 1 (1%) | N/a | N/a | 1 (8.3%) | N/a | N/a | N/a | N/a |
N/A: not applicable; N/a: not available; BMI: body mass index; SGLT2i: sodium glucose contrasnporter-2 inhibitor; TIR: time in range; CGM: continuous glucose monitoring; GI: gastrointestinal; SBG: systolic blood pressure; T2D: type 2 diabetes; eGFR: estimated glomerular filteration rate; HbA1c: glycated haemoglobin